Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? CompanAIn’s Veterinary Portal broadens its AI pet-wellness platform from owner-facing tools into a shared clinical workflow, which could make the product stickier for clinics and more valuable for longitudinal care. By giving vets ...
Featured Article Cover Story Research Updates Regulatory Approval Product Launches Elanco Launches $25 Million Venture Fund Innovation platform Elanco Animal Health plans to launch Elanco Ventures, a $25 million corporate venture platform to back early-stage animal health innovation. Key h...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
Quick Takeaways: Why It Matters? Elanco Ventures adds a structured, early-stage venture arm to Elanco’s strategy, giving the company a dedicated channel to access and co-develop emerging animal health technologies before they become mature competitors or acquisition targets. The ...
Featured Article Cover Story Research & Innovation Financing & Partnerships Product Launches Mergers & Acquisitions Regulatory Updates At a Glance Merck Animal Health Expands Poultry Tech Portfolio Acquisition Merck Animal Health has agreed to acquire TARGAN, adding advanced po...
Quick Takeaways: Why It Matters? Unlike drugs that carry safety concerns or diminishing effectiveness, LIFU aims to provide a non-invasive alternative to nerve blocks and radiofrequency ablation without systemic exposure, which could reduce reliance on medications and invasive procedures. ...
Quick Takeaways: Why It Matters? At scale (100,000+ ER visits already), AI-assisted documentation can meaningfully cut admin time, speed chart closure, and let vets and scribes reallocate hours to procedures, decision‑making, and client communication, helping VEG differentiate ...
Quick Takeaways: Why It Matters? This partnership is designed to scale Rebound High Performance PRP across the US veterinary market by combining epiq’s distribution reach with Vetirus’s product and regulatory credentials, removing a key barrier to adoption-access to e...
